The safety and activity of the oral BRAF inhibitor vemurafenib in patients with relapsed or refractory hairy cell leukemia, targeting mutant BRAF in relapsed or refractory hairy cell leukemia - BRAF v600e is the genetic lesion underlying hairy cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients.